RCUSのチャート
RCUSの企業情報
| symbol | RCUS |
|---|---|
| 会社名 | Arcus Biosciences Inc （ARCUS BIOSCIENCS） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | Arcus Biosciences Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on the discovery and development of cancer immunotherapy. Its pipeline includes AB928 AB680 AB122 and AB154. AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.It is in the Phase-I clinical trial. AB680 is a potent and selective inhibitor of CD73 and is in the pre-clinical stage of development. AB122 is an anti-PD-1 antibody and is in the Phase-I dose-escalation trial. AB154 is a humanized anti-TIGIT antibody. ア―カス・バイオサイエンシズは米国のバイオ医薬品企業。臨床段階で、がんに対し創造的で革新的な免疫治療の開発に従事する。同社は、科学的デ―タによって十分に特徴付けられた生物学的経路を標的とし、がんに対する免疫応答の調節の重要性に焦点を当てる。本社所在地はカリフォルニア州ヘイワ―ド。 Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1. |
| 本社所在地 | 3928 Point Eden Way Hayward CA 94545 USA |
| 代表者氏名 | Juan Carlos Jaen |
| 代表者役職名 | President Co-Founder |
| 電話番号 | +1 650-489-9000 |
| 設立年月日 | 42095 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 108人 |
| url | www.arcusbio.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） -51.19500 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 557.12770 |
| 売上高 | （百万ドル） 8.35300 |
| 企業価値(EV) | （百万ドル） 300.58370 |
| 当期純利益 | （百万ドル） -49.59400 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2018 Arcus Biosciences Inc revenues increased from $1.4M to $8.4M. Net loss decreased 7% to $49.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest and other income net increase from $359K to $4.9M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.27 to -$1.43. |
RCUSのテクニカル分析
RCUSのニュース
Arcus Biosciences (NYSE:RCUS) Trading Up 5% 2023/04/02 07:36:45 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was up 5% during mid-day trading on Friday . The stock traded as high as $18.34 and last traded at $18.33. Approximately 37,462 shares traded hands during trading, a decline of 97% from the average daily volume of 1,090,225 shares. The stock had previously closed at $17.46. Wall […]
Arcus Biosciences (NYSE:RCUS) Trading 5% Higher 2023/04/02 07:00:42 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating)’s share price traded up 5% during trading on Friday . The company traded as high as $18.34 and last traded at $18.33. 37,462 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,090,225 shares. The stock had previously closed at $17.46. […]
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results 2023/03/23 04:58:07 Seeking Alpha
Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study. See why RCUS stock is a Buy.
Arcus Biosciences Files Mixed Shelf 2023/03/01 11:01:01 Investing.com
https://www.investing.com/news/assorted/arcus-biosciences-files-mixed-shelf-432SI-3018317
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update 2023/02/28 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple c
Arcus Biosciences (NYSE:RCUS) Trading Up 5% 2023/04/02 07:36:45 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was up 5% during mid-day trading on Friday . The stock traded as high as $18.34 and last traded at $18.33. Approximately 37,462 shares traded hands during trading, a decline of 97% from the average daily volume of 1,090,225 shares. The stock had previously closed at $17.46. Wall […]
Arcus Biosciences (NYSE:RCUS) Trading 5% Higher 2023/04/02 07:00:42 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating)’s share price traded up 5% during trading on Friday . The company traded as high as $18.34 and last traded at $18.33. 37,462 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,090,225 shares. The stock had previously closed at $17.46. […]
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results 2023/03/23 04:58:07 Seeking Alpha
Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study. See why RCUS stock is a Buy.
Arcus Biosciences Files Mixed Shelf 2023/03/01 11:01:01 Investing.com
https://www.investing.com/news/assorted/arcus-biosciences-files-mixed-shelf-432SI-3018317
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update 2023/02/28 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple c
Arcus Biosciences (NYSE:RCUS) Trading Up 5% 2023/04/02 07:36:45 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was up 5% during mid-day trading on Friday . The stock traded as high as $18.34 and last traded at $18.33. Approximately 37,462 shares traded hands during trading, a decline of 97% from the average daily volume of 1,090,225 shares. The stock had previously closed at $17.46. Wall […]
Arcus Biosciences (NYSE:RCUS) Trading 5% Higher 2023/04/02 07:00:42 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating)’s share price traded up 5% during trading on Friday . The company traded as high as $18.34 and last traded at $18.33. 37,462 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,090,225 shares. The stock had previously closed at $17.46. […]
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results 2023/03/23 04:58:07 Seeking Alpha
Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study. See why RCUS stock is a Buy.
Arcus Biosciences Files Mixed Shelf 2023/03/01 11:01:01 Investing.com
https://www.investing.com/news/assorted/arcus-biosciences-files-mixed-shelf-432SI-3018317
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update 2023/02/28 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple c